Lantheus
LNTH
Workday
WDAY
Hutchmed (China)
HCM
DexCom
DXCM
Halozyme Therapeutics
HALO
US Stock MarketDetailed Quotes
ACTU Actuate Therapeutics
- 7.290
- +0.230+3.26%
Trading Feb 26 11:03 ET
142.39MMarket Cap-5.00P/E (TTM)
7.631High7.000Low8.65KVolume7.230Open7.060Pre Close63.23KTurnover0.13%Turnover RatioLossP/E (Static)19.53MShares11.73052wk High26.61P/B48.08MFloat Cap5.51052wk Low--Dividend TTM6.60MShs Float11.730Historical High--Div YieldTTM8.94%Amplitude5.510Historical Low7.312Avg Price1Lot Size
Actuate Therapeutics Stock Forum
Actuate Announces Completion of Enrollment in a Phase 2 Trial of Elraglusib in Combination with FOLFIRINOX and Losartan in Patients with Previously Untreated Metastatic Pancreatic Cancer
Tuesday, 25th February at 8:00 am
• Initial Data from this Phase 2 Trial Demonstrates Early Evidence of Clinical Activity of Elraglusib (9-ING-41) in Combination with FOLFIRINOX and Losartan in Untreated Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)
• The Final Results...
Actuate Therapeutics Receives EMA Orphan Medicinal Product Designation for Elraglusib for the Treatment of Pancreatic Cancer
Tuesday, 7th January at 8:00 am
CHICAGO and FORT WORTH, Texas, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) ("Actuate" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen...
1. NFA
2. Do not open position without chart confirmation, indicators, momentum.
3. Check current shorts availability on FINTEL.io
4. Scale out and secure profits
5. Always remember shorts include dark pools.
6. Most importantly, don’t blame for your losses. I already give watchlist and stock education. The ball is on you.
$KULR Technology (KULR.US)$ PR 12/17: Signs Service Agreement to Launch KULR ONE Space Battery. COH $13.4M good for 9 months✅
$Wearable Devices (WLDS.US)$ PR 12/17:...
Actuate Therapeutics Announces Positive Interim Phase 2 Data of Elraglusib in First Line Treatment of Metastatic Pancreatic Cancer
Tuesday, 17th December at 8:00 am
• Statistical Significance Met on Primary Endpoints of 1 Year Survival Rate and Median Overall Survival
• Doubling of 1 Year Survival Rate and 37% Reduction in Risk of Death
• Two Month (29%) Increase in Median Overall Survival
• Multiple Patients with Complete Responses (CRs) and/or Partial Re...
CHICAGO and FORT WORTH, Texas, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company, focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β), announced that it will participate in “Webinar Wednesday” hosted b...
No comment yet